How does ATAI's projected 2026 annual revenue compare to its key psychedelic therapy peers?

ATAI Life Sciences N.V. (ATAI) is projected to have significantly higher annual revenue in 2026 compared to several of its key psychedelic therapy peers.

2026 Projected Annual Revenue Comparison

• ATAI Life Sciences N.V. (ATAI): Analysts forecast an annual revenue of $184 million for the fiscal year ending December 31, 2026, based on estimates from 8 analysts.1
• COMPASS Pathways plc (CMPS): For the same period ending December 31, 2026, COMPASS Pathways has a projected annual revenue of $49 million, derived from 9 analysts.2
• Mind Medicine (MindMed) Inc. (MMED): MindMed's projected annual revenue for the fiscal year ending December 31, 2026, stands at $35 million, with estimates from 7 analysts.3
• Cybin Inc. (CYBN): Cybin Inc. is projected to have $0 million in annual revenue for the fiscal year ending March 31, 2026, according to estimates from 5 analysts.4

This data suggests that ATAI is anticipated to lead its listed peers in revenue generation for 2026, indicating a more advanced stage in commercialization or a stronger pipeline with nearer-term revenue potential as perceived by analysts. It's important to note that many companies in the psychedelic therapy space are still in clinical development stages, and revenue projections can be highly speculative. ATAI, for instance, is advancing several psychedelic-based therapies, including BPL-003 for treatment-resistant depression (TRD), VLS-01 for TRD, and EMP-01 for social anxiety disorder, all of which are in Phase 2 clinical development.5